TRVI
Price:
$3.97
Market Cap:
$354.78M
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.[Read more]
Industry
Biotechnology
IPO Date
2019-05-07
Stock Exchange
NASDAQ
Ticker
TRVI
According to Trevi Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 339.84M. This represents a change of 32.38% compared to the average of 256.72M of the last 4 quarters.
The mean historical Enterprise Value of Trevi Therapeutics, Inc. over the last ten years is 58.53M. The current 339.84M Enterprise Value has changed 57.96% with respect to the historical average. Over the past ten years (40 quarters), TRVI's Enterprise Value was at its highest in in the September 2024 quarter at 322.54M. The Enterprise Value was at its lowest in in the December 2017 quarter at -13318630.00.
Average
58.53M
Median
54.33M
Minimum
-12947821.25
Maximum
141.16M
Discovering the peaks and valleys of Trevi Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.23%
Maximum Annual Enterprise Value = 141.16M
Minimum Annual Increase = -2895.20%
Minimum Annual Enterprise Value = -12947821.25
Year | Enterprise Value | Change |
---|---|---|
2023 | 101.65M | -16.10% |
2022 | 121.15M | -2895.20% |
2021 | -4334393.56 | -133.57% |
2020 | 12.91M | -199.73% |
2019 | -12947821.25 | -123.68% |
2018 | 54.67M | 1.23% |
2017 | 54.00M | -61.74% |
The current Enterprise Value of Trevi Therapeutics, Inc. (TRVI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
72.82M
5-year avg
43.69M
10-year avg
58.53M
Trevi Therapeutics, Inc.’s Enterprise Value is greater than aTyr Pharma, Inc. (138.44M), greater than Cue Biopharma, Inc. (41.71M), greater than AN2 Therapeutics, Inc. (6.98M), greater than BioAtla, Inc. (-24961978.00), greater than Spero Therapeutics, Inc. (-20557187.00), greater than Bolt Biotherapeutics, Inc. (28.60M), greater than Coherus BioSciences, Inc. (303.85M), less than Gracell Biotechnologies Inc. (5.66B), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Foghorn Therapeutics Inc. (261.58M), greater than C4 Therapeutics, Inc. (278.51M), greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than Prelude Therapeutics Incorporated (69.78M), greater than Rezolute, Inc. (244.24M), greater than Lyra Therapeutics, Inc. (22.74M), greater than SQZ Biotechnologies Company (12.09M), greater than Protara Therapeutics, Inc. (129.55M), greater than TRACON Pharmaceuticals, Inc. (-6160275.00), greater than Seer, Inc. (122.73M), less than ORIC Pharmaceuticals, Inc. (533.31M), greater than Anebulo Pharmaceuticals, Inc. (38.14M), less than Cullinan Oncology, Inc. (615.40M),
Company | Enterprise Value | Market cap |
---|---|---|
138.44M | $131.12M | |
41.71M | $64.62M | |
6.98M | $40.49M | |
-24961978.00 | $30.30M | |
-20557187.00 | $51.11M | |
28.60M | $19.79M | |
303.85M | $169.92M | |
5.66B | $989.87M | |
-6333315.00 | $8.20M | |
261.58M | $280.19M | |
278.51M | $271.06M | |
-20511738.00 | $108.71M | |
69.78M | $62.77M | |
244.24M | $252.63M | |
22.74M | $11.22M | |
12.09M | $12.83M | |
129.55M | $176.58M | |
-6160275.00 | $109.72K | |
122.73M | $133.85M | |
533.31M | $574.42M | |
38.14M | $39.55M | |
615.40M | $715.03M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Trevi Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Trevi Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Trevi Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Trevi Therapeutics, Inc. (TRVI)?
What is the 3-year average Enterprise Value for Trevi Therapeutics, Inc. (TRVI)?
What is the 5-year average Enterprise Value for Trevi Therapeutics, Inc. (TRVI)?
How does the current Enterprise Value for Trevi Therapeutics, Inc. (TRVI) compare to its historical average?